Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
5th
years
Home>>Products>>cas 155213-67-5 99% Ritonavir powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile:

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

cas 155213-67-5 99% Ritonavir powder

CAS NO.155213-67-5

  • Min.Order: 100 Gram
  • Payment Terms: L/C,T/T,MoneyGram
Contact Supplier

Product Details

Keywords

  • Ritonavir powder
  • Ritonavir
  • 99% Ritonavir powder

Quick Details

  • ProName: cas 155213-67-5 99% Ritonavir powder
  • CasNo: 155213-67-5
  • Molecular Formula: C37H48N6O5S2
  • Appearance: white
  • Application: anti antiviral
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Day
  • Purity: 99
  • Storage: room
  • LimitNum: 100 Gram

Superiority

 

MOQ: 1kg
Form: Powder
Colour: White
Test: HPLC
Function: anti   antiviral 
Grade: Pharm

 

Details

cas 155213-67-5 99% Ritonavir powder 

 Product Name:    Ritonavir
CAS:    155213-67-5
MF:    C37H48N6O5S2
MW:    720.94
EINECS:    605-001-5
Melting point     120-122°C
Boiling point     947.0±65.0 °C(Predicted)
density     1.239±0.06 g/cm3(Predicted)
storage temp.     room temp
solubility     DMSO: soluble10mg/mL 
form     powder
color     white to beige 

It is an inhibitor of HIV aspartic protease which is critical in the processing of a propeptide into the gag, gag-pol gene products and the protease itself. This inhibition results in the release of non-infectous immature virus particles. It is greater than 500-fold more selective for viral aspartic protease than the human version, has good oral bioavailability and may increase the bioavailability of other protease inhibitors. Ritonavir was able to increase the CD4 and CD8 lymphocyte count as well as reduce viral RNA. It is more potent than saqunavir and comparible in potency to zidovudine and lamivudine.
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients.